Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel
about
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer.Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancerPrognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancerPretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancerNeutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsyThe effectiveness of the TAX 327 nomogram in predicting overall survival in Chinese patients with metastatic castration-resistant prostate cancer.Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer.Lack of an association between the aPKCλ/ι expression in prostate cancer and the patient outcomes.The Effects of Different Doses and Patterns of Docetaxel Chemotherapy in Japanese Patients with Castration-Resistant Prostate Cancer.Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing.Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer.
P2860
Q34569684-E3A18D69-F7A9-4E97-B782-7747E7295252Q34569689-D8A99074-5DFD-4E66-AA2C-4957D1F2305DQ35151347-E80964C1-0962-41AF-A1A4-5FEF935DA21CQ35713138-BD348569-0863-4E7B-AE1A-3563738BFD98Q35925260-A0BB4806-6CA2-4119-85F9-A4E5F9246269Q35925423-7578EC10-84B1-47F7-8CE5-72BDB173B4DCQ36544801-39283294-EEB9-4AF3-9D46-A44D1AD3C971Q37437063-4A25150D-C88C-4E50-B1C9-D4D185064F73Q38795167-B3CEF756-2DA5-4692-A717-31308E8E849CQ40755361-2CF5F248-864E-4EFC-AFF9-F6146767B357Q40974176-C064552B-9A15-455B-BD0F-2F74BC17642EQ42353380-88DBB4A9-3FE2-4D9F-B887-FD43B74F6F23Q51313699-5E53B715-D786-4FD1-9491-369EC4B77927Q54542174-6EBF5ABE-CA52-4560-A09D-B230FA3F6AB9
P2860
Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Risk factors for metastatic ca ...... -term treatment with docetaxel
@ast
Risk factors for metastatic ca ...... -term treatment with docetaxel
@en
Risk factors for metastatic castration-resistant prostate cancer
@nl
type
label
Risk factors for metastatic ca ...... -term treatment with docetaxel
@ast
Risk factors for metastatic ca ...... -term treatment with docetaxel
@en
Risk factors for metastatic castration-resistant prostate cancer
@nl
prefLabel
Risk factors for metastatic ca ...... -term treatment with docetaxel
@ast
Risk factors for metastatic ca ...... -term treatment with docetaxel
@en
Risk factors for metastatic castration-resistant prostate cancer
@nl
P2093
P2860
P1433
P1476
Risk factors for metastatic ca ...... -term treatment with docetaxel
@en
P2093
Futoshi Sano
Hiroji Uemura
Hiroshi Misaki
Jun-ichi Teranishi
Kazumi Noguchi
Narihiko Hayashi
Takashi Kawahara
Yasuhide Miyoshi
Yoshinobu Kubota
Zenkichi Sekiguchi
P2860
P304
P356
10.1371/JOURNAL.PONE.0048186
P407
P577
2012-10-30T00:00:00Z